Showing results (231-240 of 289) with videos related to
Sort By:
Pageof 29
Der Urologe. Ausg. A|July 11, 2007
[Effect of disturbing factors on the specificity of exfoliative urinary cytology]Y Busch, F vom Dorp, M Schenck, et al.Der Urologe. Ausg. A|July 1, 2008
[Value of targeted therapy for prostate cancer]C Börgermann, F Vom Dorp, M Schenck, et al.Der Urologe. Ausg. A|August 24, 2014
[Transitional cell carcinoma of the bladder: bladder-sparing therapy]F Vom Dorp, S Tschirdewahn, T Szarvas, et al.Der Urologe. Ausg. A|August 15, 2009
[Informed consent for patients on early recognition of prostate carcinoma is insufficient]C Börgermann, F vom Dorp, R Rossi, et al.Cancer Research|June 15, 1994
Inverse relation of E-cadherin and autocrine motility factor receptor expression as a prognostic factor in patients with bladder carcinomasT Otto, W Birchmeier, U Schmidt, et al.Transplant International : Official Journal of the European Society for Organ Transplantation|December 1, 1988
Enhancement of chemically induced bladder carcinoma by cyclosporin AF Recker, H Rübben, A Homburg, et al.Aktuelle Radiologie|March 1, 1996
[Use of digital luminescence radiography in voiding cystourethrography]C Gocke, P Gocke, R D Müller, et al.British Journal of Urology|May 23, 1998
Free-to-total prostate-specific antigen (PSA) ratio improves the specificity for detecting prostate cancer in patients with prostatism and intermediate PSA levelsF Recker, M K Kwiatkowski, T Piironen, et al.Der Urologe. Ausg. A|March 9, 2005
[Therapy for overactive detrusor using propiverine]S Alloussi, M Goepel, A E Richter, et al.Der Urologe. Ausg. A|July 17, 1999
[Effectiveness and tolerance of 1 dosage forms (subcutaneous and intramuscular) of decapeptyl depot in patients with advanced prostate carcinoma]K F Klippel, C J Winkler, D Jocham, et al.Pageof 29